The DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
Parkinson's disease: Mechanisms, translational models and management strategies
Abstract
&NA; Parkinson's disease is a progressive neurodegenerative disorder. The classical motor symptoms include resting tremors, bradykinesia, rigidity and postural instability and are accompanied by the loss of dopaminergic neurons and Lewy pathology. Diminished neurotransmitter level, oxidative stress, mitochondrial dysfunction and perturbed protein homeostasis over time worsen the disease manifestations in elderly people. Current management strategies aim to provide symptomatic relief and to slow down the disease progression. However, no pharmacological breakthrough has been made to protect dopaminergic neurons and associated motor circuitry components. Deep brain stimulation, stem cells‐derived dopaminergic neurons transplantation, gene editing and gene transfer remain promising approaches for the potential management of neurodegenerative disease. Toxin or genetically induced rodent models replicating Parkinson's disease pathology are of high predictive value for translational research. This review addresses the current understanding, management strategies and the Parkinson's disease models for translational research. Preclinical research may provide powerful tools to quest the potential therapeutic and neuroprotective compounds for dopaminergic neurons and hence possible cure for the Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 1×
“Early symptoms may include sleep and associated disorders such as, mild tremors, soft speech, postural difficulty, impairments in normal facial expressions, reduced limb movement, focus loss, general fatigue and depression without any obvious cause [17].”
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
The functional anatomy of basal ganglia disorders
Albin, R. L., Young, A. B., & Penney, J. B. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90074-x · Cited by 5,353
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., Giladi, N., Holloway, R. G., Moore, C. G., Wenning, G. K., et al. (2004) · Movement Disorders · doi:10.1002/mds.20213 · Cited by 2,347
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, K. R., & Schapira, A. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,738
Braak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683
Volpicelli-Daley, L. A., Luk, K. C., Patel, T. P., Tanik, S. A., Riddle, D. M., Stieber, A., Meaney, D. F., Trojanowski, J. Q., & Lee, V. M.-Y. (2011) · Neuron · doi:10.1016/j.neuron.2011.08.033 · Cited by 1,569
Barone, P., Antonini, A., Colosimo, C., Marconi, R., Morgante, L., Avarello, T. P., Bottacchi, E., Cannas, A., Ceravolo, G., Ceravolo, R., et al. (2009) · Movement Disorders · doi:10.1002/mds.22643 · Cited by 1,445
Prevalence and Characteristics of Dementia in Parkinson Disease: An 8-Year Prospective Study
Aarsland, D., Andersen, K., Larsen, J. P., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,401
Benabid, A. L., Pollak, P., Louveau, A., Henry, S., & de Rougemont, J. (1987) · Stereotactic and Functional Neurosurgery · doi:10.1159/000100803 · Cited by 1,378
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease
Auluck, P. K., Chan, H. Y. E., Trojanowski, J. Q., Lee, V. M.-Y., & Bonini, N. M. (2002) · Science · doi:10.1126/science.1067389 · Cited by 1,227
Grafts of Fetal Dopamine Neurons Survive and Improve Motor Function in Parkinson's Disease
Lindvall, O., Brundin, P., Widner, H., Rehncrona, S., Gustavii, B., Frackowiak, R., Leenders, K. L., Sawle, G., Rothwell, J. C., Marsden, C. D., et al. (1990) · Science · doi:10.1126/science.2105529 · Cited by 1,207
Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease
Ibáñez, P., Bonnet, A.-M., Débarges, B., Lohmann, E., Tison, F., Agid, Y., Dürr, A., Brice, A., & Pollak, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17104-3 · Cited by 1,044
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I., Quinn, N., Sethi, K. D., Shults, C., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,009
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Bronstein, J. M., Tagliati, M., Alterman, R. L., Lozano, A. M., Volkmann, J., Stefani, A., Horak, F. B., Okun, M. S., Foote, K. D., Krack, P., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.260 · Cited by 971
Iranzo, A., Molinuevo, J. L., Santamaría, J., Serradell, M., Martí, M. J., Valldeoriola, F., & Tolosa, E. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70476-8 · Cited by 952
Pathophysiology of bradykinesia in Parkinson's disease
Berardelli, A. (2001) · Brain · doi:10.1093/brain/124.11.2131 · Cited by 906
Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 849
The role of mitochondria in reactive oxygen species metabolism and signaling
Starkov, A. A. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.015 · Cited by 846 · cited 1×
“H2O2 is subsequently broken down to H2O and O2 by catalase to maintain its homeostasis [70].”
BackgroundPathophysiology of the basal ganglia in Parkinson's disease
Obeso, J. A., Rodriguez-Oroz, M. C., Rodriguez, M., Lanciego, J. L., Artieda, J., Gonzalo, N., & Olanow, C. W. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00028-8 · Cited by 844
Role of Oxidative Stress in Parkinson's Disease
Hwang, O. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.11 · Cited by 835
Classic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP
Schober, A. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0938-y · Cited by 803
The basal ganglia communicate with the cerebellum
Bostan, A. C., Dum, R. P., & Strick, P. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000496107 · Cited by 780
Odekerken, V. J., van Laar, T., Staal, M. J., Mosch, A., Hoffmann, C. F., Nijssen, P. C., Beute, G. N., van Vugt, J. P., Lenders, M. W., Contarino, M. F., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70264-8 · Cited by 763
The cerebellum in Parkinson’s disease
Wu, T., & Hallett, M. (2013) · Brain · doi:10.1093/brain/aws360 · Cited by 748
Keeney, P. M., Xie, J., Capaldi, R. A., & Bennett, J. P. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0984-06.2006 · Cited by 747
Volpicelli-Daley, L. A., Luk, K. C., & Lee, V. M.-Y. (2014) · Nature Protocols · doi:10.1038/nprot.2014.143 · Cited by 731
Kim, R. H., Smith, P. D., Aleyasin, H., Hayley, S., Mount, M. P., Pownall, S., Wakeham, A., You-Ten, A. J., Kalia, S. K., Horne, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501282102 · Cited by 701
The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice
Manning-Bog, A. B., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L., & Di Monte, D. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c100560200 · Cited by 684
α-Synuclein misfolding and Parkinson's disease
Breydo, L., Wu, J. W., & Uversky, V. N. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.002 · Cited by 657
Depression in Parkinson disease—epidemiology, mechanisms and management
Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U., & Svenningsson, P. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.189 · Cited by 593
Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?
Helmich, R. C., Hallett, M., Deuschl, G., Toni, I., & Bloem, B. R. (2012) · Brain · doi:10.1093/brain/aws023 · Cited by 581
The epidemiology of dementia associated with Parkinson disease
Aarsland, D., & Kurz, M. W. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.034 · Cited by 578
Goldberg, M. S., Pisani, A., Haburcak, M., Vortherms, T. A., Kitada, T., Costa, C., Tong, Y., Martella, G., Tscherter, A., Martins, A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.041 · Cited by 538
de Rijk, M. C., Launer, L. J., Berger, K., Breteler, M. M. B., Dartigues, J. F., Baldereschi, M., Fratiglioni, L., Lobo, A., Martinez-Lage, J., Trenkwalder, C., et al. (2000) · PubMed · Cited by 528
Fornai, F., Schlüter, O. M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C. L., Pontarelli, F., Battaglia, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409713102 · Cited by 526
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
MPTP Mouse Models of Parkinson's Disease: An Update
Meredith, G. E., & Rademacher, D. J. (2011) · Journal of Parkinson’s Disease · doi:10.3233/jpd-2011-11023 · Cited by 514
Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R. J., & Shen, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004676107 · Cited by 501
Oorschot, D. E. (1996) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19960318)366:4<580::aid-cne3>3.0.co;2-0 · Cited by 499
A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
(2004) · Archives of Neurology · doi:10.1001/archneur.61.4.561 · Cited by 485
Warren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A. H., Emre, M., Nissinen, H., Leinonen, M., Stocchi, F., & Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) Investigators (2013) · Movement Disorders · doi:10.1002/mds.25364 · Cited by 484
Parkin-deficient mice are not a robust model of parkinsonism
Perez, F. A., & Palmiter, R. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409598102 · Cited by 477
Orimo, S., Uchihara, T., Nakamura, A., Mori, F., Kakita, A., Wakabayashi, K., & Takahashi, H. (2008) · Brain · doi:10.1093/brain/awm302 · Cited by 462
Wright Willis, A., Evanoff, B. A., Lian, M., Criswell, S. R., & Racette, B. A. (2010) · Neuroepidemiology · doi:10.1159/000275491 · Cited by 436
α-Synuclein and neuronal cell death
Cookson, M. R. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-9 · Cited by 418
The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T. S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.131 · Cited by 408
PD MED Collaborative Group (2014) · The Lancet · doi:10.1016/s0140-6736(14)60683-8 · Cited by 407
Review: Sporadic Parkinson's disease: development and distribution of α‐synuclein pathology
Del Tredici, K., & Braak, H. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12298 · Cited by 398
The role of parkin in familial and sporadic Parkinson's disease
Dawson, T. M., & Dawson, V. L. (2010) · Movement Disorders · doi:10.1002/mds.22798 · Cited by 392
Neuroprotective Function of DJ-1 in Parkinson’s Disease
Ariga, H., Takahashi-Niki, K., Kato, I., Maita, H., Niki, T., & Iguchi-Ariga, S. M. M. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/683920 · Cited by 373
Liu, S., Sawada, T., Lee, S., Yu, W., Silverio, G., Alapatt, P., Millan, I., Shen, A., Saxton, W., Kanao, T., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002537 · Cited by 371
Cleeter, M. W. J., Cooper, J. M., & Schapira, A. H. V. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09789.x · Cited by 371
Ledford, H. (2015) · Nature · doi:10.1038/522020a · Cited by 344
The Epidemiology of Dementia Associated with Parkinson's Disease
Aarsland, D., & Kurz, M. W. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00369.x · Cited by 338
Shin, Y., Klucken, J., Patterson, C., Hyman, B. T., & McLean, P. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503326200 · Cited by 329
Wang, W., Wang, X., Fujioka, H., Hoppel, C., Whone, A. L., Caldwell, M. A., Cullen, P. J., Liu, J., & Zhu, X. (2016) · Nature Medicine · doi:10.1038/nm.3983 · Cited by 324
de Dreu, M. J., van der Wilk, A. S. D., Poppe, E., Kwakkel, G., & van Wegen, E. E. H. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70036-0 · Cited by 322
Li, W., Englund, E., Widner, H., Mattsson, B., van Westen, D., Lätt, J., Rehncrona, S., Brundin, P., Björklund, A., Lindvall, O., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605245113 · Cited by 313
Sterky, F. H., Lee, S., Wibom, R., Olson, L., & Larsson, N.-G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103295108 · Cited by 299
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294
Gorbatyuk, O. S., Li, S., Sullivan, L. F., Chen, W., Kondrikova, G., Manfredsson, F. P., Mandel, R. J., & Muzyczka, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711053105 · Cited by 293
Mechanisms and Targets of Deep Brain Stimulation in Movement Disorders
Johnson, M. D., Miocinovic, S., McIntyre, C. C., & Vitek, J. L. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.010 · Cited by 291
Rajput, A. H. (2014) · Movement Disorders · doi:10.1002/mds.25800 · Cited by 290
Decressac, M., Mattsson, B., Lundblad, M., Weikop, P., & Björklund, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.013 · Cited by 286
Role of oxidative stress in paraquat‐induced dopaminergic cell degeneration
McCormack, A. L., Atienza, J. G., Johnston, L. C., Andersen, J. K., Vu, S., & Di Monte, D. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03088.x · Cited by 278
Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., & Lee, V. M.-Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412621200 · Cited by 273
Prevalence of orthostatic hypotension
Low, P. A. (2008) · Clinical Autonomic Research · doi:10.1007/s10286-007-1001-3 · Cited by 271
Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal–lysosomal pathway
Tofaris, G. K., Kim, H. T., Hourez, R., Jung, J.-W., Kim, K. P., & Goldberg, A. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109356108 · Cited by 271
Sedelis, M., Hofele, K., Auburger, G. W., Morgan, S., Huston, J. P., & Schwarting, R. K. W. (2000) · Behavior Genetics · doi:10.1023/a:1001958023096 · Cited by 252
Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease
Chung, K. A., Lobb, B. M., Nutt, J. G., & Horak, F. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f6128c · Cited by 252
Behavioral models of Parkinson's disease in rodents: A new look at an old problem
Meredith, G. E., & Kang, U. J. (2006) · Movement Disorders · doi:10.1002/mds.21010 · Cited by 250
MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects.
Langston, J. W., Langston, E. B., & Irwin, I. (1984) · PubMed · Cited by 249
α-Synuclein gene duplication is present in sporadic Parkinson disease
Ahn, T. B., Kim, S. Y., Kim, J. Y., Park, S. S., Lee, D. S., Min, H. J., Kim, Y. K., Kim, S. E., Kim, J. M., Kim, H. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000271080.53272.c7 · Cited by 249
Circadian and sleep disorders in Parkinson's disease
Videnovic, A., & Golombek, D. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.08.018 · Cited by 245
ANDERSON, G., NOORIAN, A., TAYLOR, G., ANITHA, M., BERNHARD, D., SRINIVASAN, S., & GREENE, J. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.010 · Cited by 238
Cognitive impairment in Parkinson's disease
Verbaan, D., Marinus, J., Visser, M., van Rooden, S. M., Stiggelbout, A. M., Middelkoop, H. A. M., & van Hilten, J. J. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.112367 · Cited by 235
Kim, S. D., Allen, N. E., Canning, C. G., & Fung, V. S. C. (2013) · CNS Drugs · doi:10.1007/s40263-012-0012-3 · Cited by 234
Effects of exercise on mobility in people with Parkinson's disease
van der Kolk, N. M., & King, L. A. (2013) · Movement Disorders · doi:10.1002/mds.25658 · Cited by 234
Advances in closed-loop deep brain stimulation devices
Parastarfeizabadi, M., & Kouzani, A. Z. (2017) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-017-0295-1 · Cited by 232
Li, X., Tan, Y., Poulose, S., Olanow, C. W., Huang, X., & Yue, Z. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04743.x · Cited by 230
Uhl, G. R., Hedreen, J. C., & Price, D. L. (1985) · Neurology · doi:10.1212/wnl.35.8.1215 · Cited by 230
Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity
Gash, D. M., Rutland, K., Hudson, N. L., Sullivan, P. G., Bing, G., Cass, W. A., Pandya, J. D., Liu, M., Choi, D., Hunter, R. L., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21288 · Cited by 222
Mitophagy and Parkinson's disease: The PINK1–parkin link
Deas, E., Wood, N. W., & Plun-Favreau, H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.08.007 · Cited by 222
Neuronal Mitophagy in Neurodegenerative Diseases
Martinez-Vicente, M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00064 · Cited by 216
Yu, W., Sun, Y., Guo, S., & Lu, B. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr235 · Cited by 213
Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3
Rappold, P. M., Cui, M., Chesser, A. S., Tibbett, J., Grima, J. C., Duan, L., Sen, N., Javitch, J. A., & Tieu, K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115141108 · Cited by 209
Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease
Buddhala, C., Loftin, S. K., Kuley, B. M., Cairns, N. J., Campbell, M. C., Perlmutter, J. S., & Kotzbauer, P. T. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.246 · Cited by 206
Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease
Zeng, X.-S., Geng, W.-S., Jia, J.-J., Chen, L., & Zhang, P.-P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00109 · Cited by 193
Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
Müller, T. (2015) · Drugs · doi:10.1007/s40265-014-0343-0 · Cited by 190
da Silva, F. C., Iop, R. D. R., de Oliveira, L. C., Boll, A. M., de Alvarenga, J. G. S., Gutierres Filho, P. J. B., de Melo, L. M. A. B., Xavier, A. J., & da Silva, R. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193113 · Cited by 189
Chen, L., Xie, Z., Turkson, S., & Zhuang, X. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0089-14.2015 · Cited by 187
Cognitive decline in Parkinson’s disease: the complex picture
Biundo, R., Weis, L., & Antonini, A. (2016) · npj Parkinson s Disease · doi:10.1038/npjparkd.2016.18 · Cited by 187
Choi, W.-S., Palmiter, R. D., & Xia, Z. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009132 · Cited by 183
Bonito-Oliva, A., Masini, D., & Fisone, G. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00290 · Cited by 179
Lu, X.-H., Fleming, S. M., Meurers, B., Ackerson, L. C., Mortazavi, F., Lo, V., Hernandez, D., Sulzer, D., Jackson, G. R., Maidment, N. T., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5351-08.2009 · Cited by 178
Karampetsou, M., Ardah, M. T., Semitekolou, M., Polissidis, A., Samiotaki, M., Kalomoiri, M., Majbour, N., Xanthou, G., El-Agnaf, O. M. A., & Vekrellis, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-15813-8 · Cited by 175
Ip, C. W., Klaus, L.-C., Karikari, A. A., Visanji, N. P., Brotchie, J. M., Lang, A. E., Volkmann, J., & Koprich, J. B. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0416-x · Cited by 171
Che, Y., Hou, L., Sun, F., Zhang, C., Liu, X., Piao, F., Zhang, D., Li, H., & Wang, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0468-2 · Cited by 168
Bladder and bowel dysfunction in Parkinson’s disease
Sakakibara, R., Uchiyama, T., Yamanishi, T., Shirai, K., & Hattori, T. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-007-0855-9 · Cited by 164
Fujishiro, H., Frigerio, R., Burnett, M., Klos, K. J., Josephs, K. A., DelleDonne, A., Parisi, J. E., Ahlskog, J. E., & Dickson, D. W. (2008) · Movement Disorders · doi:10.1002/mds.21989 · Cited by 163
Chinese scientists to pioneer first human CRISPR trial
Cyranoski, D. (2016) · Nature · doi:10.1038/nature.2016.20302 · Cited by 160
Quantitation of non‐motor symptoms in Parkinson’s disease
Chaudhuri, K. R., & Martinez‐Martin, P. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02212.x · Cited by 158
Nguyen, M., & Krainc, D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717590115 · Cited by 158
Gasmi, M., Herzog, C. D., Brandon, E. P., Cunningham, J. J., Ramirez, G. A., Ketchum, E. T., & Bartus, R. T. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300010 · Cited by 157
Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease
Lindenbach, D., & Bishop, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.09.008 · Cited by 154
DJ-1 Inhibits α-Synuclein Aggregation by Regulating Chaperone-Mediated Autophagy
Xu, C., Kang, W., Chen, Y., Jiang, T., Zhang, J., Zhang, L., Ding, J., Liu, J., & Chen, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00308 · Cited by 148
Andrés‐Mateos, E., Mejías, R., Sasaki, M., Li, X., Lin, B. M., Biskup, S., Zhang, L., Banerjee, R., Thomas, B., Yang, L., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4357-09.2009 · Cited by 146
Isobe, C., Abe, T., & Terayama, Y. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.065 · Cited by 139
Ungerstedt, U., Ljungberg, T., & Steg, G. (1974) · PubMed · Cited by 138
Cellular models to investigate biochemical pathways in Parkinson’s disease
Alberio, T., Lopiano, L., & Fasano, M. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08516.x · Cited by 131
Walking and talking therapy: Improving cognitive–motor dual-tasking in neurological illness
Evans, J. J., Greenfield, E., Wilson, B. A., & Bateman, A. (2009) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617708090152 · Cited by 131
Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine.
Price, K. S., Farley, I. J., & Hornykiewicz, O. (1978) · PubMed · Cited by 130
Effects of Exercise on Non-motor Symptoms in Parkinson’s Disease
Amara, A. W., & Memon, A. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.004 · Cited by 127
The Parkinson disease protein α-synuclein inhibits autophagy
Winslow, A. R., & Rubinsztein, D. C. (2011) · Autophagy · doi:10.4161/auto.7.4.14393 · Cited by 126
Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice
Sato, S., Uchihara, T., Fukuda, T., Noda, S., Kondo, H., Saiki, S., Komatsu, M., Uchiyama, Y., Tanaka, K., & Hattori, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-21325-w · Cited by 125 · cited 1×
“Aberrant protein homeostasis and PD Protein homeostasis is under intrinsic surveillance mechanisms (such as ubiquitin-protease, chaperone mediated process and autophagy system) for rapid detection of altered protein and its processing or elimination [51,52].”
BackgroundMolecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease
Stojkovska, I., Krainc, D., & Mazzulli, J. R. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2704-y · Cited by 124
Mitochondrial Quality Control and Dynamics in Parkinson's Disease
McCoy, M. K., & Cookson, M. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4019 · Cited by 116
Desai, V. G., Feuers, R. J., Hart, R. W., & Ali, S. F. (1996) · Brain Research · doi:10.1016/0006-8993(95)01255-9 · Cited by 115
Thomas, B., & Mohanakumar, K. P. (2003) · Journal of Pineal Research · doi:10.1046/j.1600-079x.2003.00096.x · Cited by 114
Preventing α-synuclein aggregation: The role of the small heat-shock molecular chaperone proteins
Cox, D., Carver, J. A., & Ecroyd, H. W. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.024 · Cited by 112
Phosphorylation, lipid raft interaction and traffic of α-synuclein in a yeast model for Parkinson
Zabrocki, P., Bastiaens, I., Delay, C., Bammens, T., Ghillebert, R., Pellens, K., VIRGILIO, C. D., LEUVEN, F. V., & Winderickx, J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.06.010 · Cited by 109
Pathogenic Mechanisms of Neurodegeneration in Parkinson Disease
Mullin, S., & Schapira, A. H. V. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2014.09.010 · Cited by 108
Mitochondria-Targeted Protective Compounds in Parkinson’s and Alzheimer’s Diseases
Fernández‐Moriano, C., González‐Burgos, E., & Gómez-Serranillos, M. P. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/408927 · Cited by 106
Ho, D. H., Je, A. R., Lee, H.-J., Son, I., Kweon, H., Kim, H., & Seol, W. (2018) · Experimental Neurobiology · doi:10.5607/en.2018.27.3.171 · Cited by 105
PINK1/Parkin-Dependent Mitochondrial Surveillance: From Pleiotropy to Parkinson's Disease
Mouton‐Liger, F., Jacoupy, M., Corvol, J., & Corti, O. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00120 · Cited by 104
Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?
deSouza, R., Moro, E., Lang, A. E., & Schapira, A. H. V. (2013) · Annals of Neurology · doi:10.1002/ana.23890 · Cited by 101
Structural effects of Parkinson's disease linked DJ‐1 mutations
Malgieri, G., & Eliezer, D. (2008) · Protein Science · doi:10.1110/ps.073411608 · Cited by 96
Chiou, S., Jiang, B.-H., Yu, Y., Chou, S., Tsai, P., Chang, W., Chen, L., Chen, L., Chien, Y., & Chiou, G. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20121044 · Cited by 95
Treatment of advanced Parkinson's disease
Giugni, J. C., & Okun, M. S. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000118 · Cited by 94
NESS, D. K., Ren, Z., Gardai, S. J., Sharpnack, D. D., Johnson, V. J., Brennan, R., Brigham, E. F., & Olaharski, A. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066164 · Cited by 93
Rousseaux, M. W. C., Marcogliese, P. C., Qu, D., Hewitt, S. J., Seang, S., Kim, R. H., Slack, R. S., Schlossmacher, M. G., Lagace, D. C., Mak, T. W., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205102109 · Cited by 91
Bartus, R. T., Kordower, J. H., Johnson, E. M., Brown, L., Kruegel, B. R., Chu, Y., Baumann, T. L., Lang, A. E., Olanow, C. W., & Herzog, C. D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.023 · Cited by 88
Parkin function in Parkinson's disease
Arkinson, C., & Walden, H. (2018) · Science · doi:10.1126/science.aar6606 · Cited by 87
Yoo, J., Noh, M., Kim, H. N., Jeon, N. L., Kim, B., & Kim, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.12.049 · Cited by 84
Lewy bodies in the enteric nervous system in Parkinson's disease.
Wakabayashi, K., Takahashi, H., Takeda, S., Ohama, E., & Ikuta, F. (1989) · Archivum histologicum japonicum · doi:10.1679/aohc.52.suppl_191 · Cited by 84
Molecular Events Underlying Parkinson’s Disease – An Interwoven Tapestry
Lim, K., & Zhang, C. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00033 · Cited by 82
Petroi, D., Popova, B., Taheri-Talesh, N., Irniger, S., Shahpasandzadeh, H., Zweckstetter, M., Outeiro, T. F., & Braus, G. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.361865 · Cited by 81
Dance is more than therapy: Qualitative analysis on therapeutic dancing classes for Parkinson’s
Rocha, P., Slade, S. C., McClelland, J. A., & Morris, M. E. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.07.006 · Cited by 81
Proteasome impairment by α-synuclein
Zondler, L., Kostka, M., Garidel, P., Heinzelmann, U., Hengerer, B., Mayer, B., Weishaupt, J. H., Gillardon, F., & Danzer, K. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184040 · Cited by 79
FACS-Assisted CRISPR-Cas9 Genome Editing Facilitates Parkinson's Disease Modeling
Arias-Fuenzalida, J., Jarazo, J., Qing, X., Walter, J., Gomez-Giro, G., Nickels, S., Zaehres, H., Schöler, H., & Schwamborn, J. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.08.026 · Cited by 78
Progranulin Gene Delivery Protects Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease
Van Kampen, J. M., Baranowski, D., & Kay, D. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097032 · Cited by 76
From the baker to the bedside: yeast models of Parkinson's disease
Menezes, R., Tenreiro, S., Macedo, D., dos Santos, C. N., & Outeiro, T. F. (2015) · Microbial Cell · doi:10.15698/mic2015.08.219 · Cited by 76
Initial management of Parkinson's disease
Goetz, C. G., & Pal, G. D. (2014) · BMJ · doi:10.1136/bmj.g6258 · Cited by 73
Effects of UCH‐L1 on α‐synuclein over‐expression mouse model of Parkinson’s disease
Yasuda, T., Nihira, T., Ren, Y., Cao, X., Wada, K., Setsuie, R., Kabuta, T., Wada, K., Hattori, N., Mizuno, Y., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05827.x · Cited by 69
Maász, G., Zrínyi, Z., Reglődi, D., Petrovics, D., Rivnyak, A., Kiss, T., Jüngling, A., Tamás, A., & Pirger, Z. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.027185 · Cited by 69
CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases
Yang, W., Tu, Z., Sun, Q., & Li, X. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00030 · Cited by 66
Zhao, F., Wang, W., Wang, C., Siedlak, S. L., Fujioka, H., Tang, B., & Zhu, X. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.02.016 · Cited by 65
Kells, A. P., Forsayeth, J., & Bankiewicz, K. S. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.004 · Cited by 63
Aron, L., Klein, P., Pham, T.-T., Kramer, E. R., Wurst, W., & Klein, R. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000349 · Cited by 61
Surgical treatment of Parkinson's disease.
Obeso, J. A., Rodriguez, M. C., Gorospe, A., Guridi, J., Álvarez, L., & Macıás, R. (1997) · PubMed · Cited by 56
The Neuroprotective Effects of Cinnamic Aldehyde in an MPTP Mouse Model of Parkinson’s Disease
Bae, W., Choi, J., & Jeong, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020551 · Cited by 56
Manalo, R. V. M., & Medina, P. M. B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00137 · Cited by 55
Milosevic, L., Gramer, R., Kim, T. H., Algarni, M., Fasano, A. A., Kalia, S. K., Hodaie, M., Lozano, A. M., Popović, M. R., & Hutchison, W. D. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.10.020 · Cited by 52
Pupyshev, A. B., Короленко, Т. А., Akopyan, A. A., Amstislavskaya, T. G., & Tikhonova, M. A. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.12.001 · Cited by 45
Stem Cells asIn VitroModel of Parkinson's Disease
Martínez‐Morales, P., & Liste, I. (2012) · Stem Cells International · doi:10.1155/2012/980941 · Cited by 44
Lee, Y.-T. C., & Hsu, S. D. (2016) · Current Protein and Peptide Science · doi:10.2174/1389203717666160217143721 · Cited by 42
The α-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease
McGeer, P. L., & McGeer, E. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.04.008 · Cited by 41
Isaacson, S., & Skettini, J. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s53983 · Cited by 41
Stroupe, K. T., Weaver, F. M., Cao, L., Ippolito, D., Barton, B. R., Burnett‐Zeigler, I., Holloway, R. G., Vickrey, B. G., Simuni, T., & Follett, K. A. (2014) · Movement Disorders · doi:10.1002/mds.26029 · Cited by 41
Neuroimaging advances in Parkinson's disease
Rispoli, V., Schreglmann, S. R., & Bhatia, K. P. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000584 · Cited by 40
Conceptualization and validation of an open-source closed-loop deep brain stimulation system in rat
Wu, H., Ghekiere, H., Beeckmans, D., Tambuyzer, T., van Kuyck, K., Aerts, J., & Nuttin, B. (2015) · Scientific Reports · doi:10.1038/srep09921 · Cited by 36
Kim, D., Hwang, H., Choi, S., Kwon, S. H., Lee, S.-H., Park, J. H., Kim, S., & Ko, H. S. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0538-9 · Cited by 36
Búzás, B., & Max, M. B. (2004) · Neurology · doi:10.1212/01.wnl.0000130384.56476.75 · Cited by 35
The Surgical Treatment of Parkinson's Disease
Baker, K. A. (1998) · Dalhousie Medical Journal · doi:10.15273/dmj.vol26no1.4421 · Cited by 34
Combined stereotactic thalamotomy and posteroventral pallidotomy for Parkinson's disease
Iacono, R. P., Henderson, J. M., & Lonser, R. R. (1995) · Journal of Image Guided Surgery · doi:10.1002/(sici)1522-712x(1995)1:3<133::aid-igs2>3.0.co;2-b · Cited by 31
A yeast model of the Parkinson׳s disease-associated protein Parkin
Pereira, C., Costa, V., Martins, L. M., & Saraiva, L. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.02.018 · Cited by 31
Distinct Mechanisms of Pathogenic DJ-1 Mutations in Mitochondrial Quality Control
Strobbe, D., Robinson, A. A., Harvey, K., Rossi, L., Ferraina, C., de Biase, V., Rodolfo, C., Harvey, R. J., & Campanella, M. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00068 · Cited by 30
Intrinsic circuits of the striatum: Complexity and clinical correlations
Benarroch, E. E. (2016) · Neurology · doi:10.1212/wnl.0000000000002599 · Cited by 25
Kojima, W., Kujuro, Y., Okatsu, K., Queliconi, B. B., Koyano, F., Kimura, M., Yamano, K., Tanaka, K., & Matsuda, N. (2016) · Genes to Cells · doi:10.1111/gtc.12382 · Cited by 23
ATP13A2 novel mutations causing a rare form of juvenile-onset Parkinson disease
Suleiman, J., Hamwi, N., & El‐Hattab, A. W. (2018) · Brain and Development · doi:10.1016/j.braindev.2018.05.017 · Cited by 19
Bains, M., & Roberts, J. L. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.10.054 · Cited by 18
Studer, V., Maestri, R., Clerici, I., Spina, L., Zivi, I., Ferrazzoli, D., & Frazzitta, G. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171126 · Cited by 18
The Application of Palliative Care Principles in Advanced Parkinson’s Disease
Sethi, S., & Hohler, A. D. (2016) · Advances in Parkinson s Disease · doi:10.4236/apd.2016.54010 · Cited by 4
Cited by
Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments
Zuo, L., Prather, E. R., Stetskiv, M., Garrison, D. E., Meade, J. R., Peace, T. I., & Zhou, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184472 · Cited by 539
Chen, H.-X., Liang, F.-C., Gu, P., Xu, B.-L., Xu, H.-J., Wang, W.-T., Hou, J.-Y., Xie, D.-X., Chai, X.-Q., & An, S.-J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2473-5 · Cited by 319
Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview
Sivandzade, F., & Cucullo, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042153 · Cited by 224
Wang, J., Li, Z., Pan, M., Fiaz, M., Hao, Y., Yan, Y., Sun, L., & Yan, F. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114539 · Cited by 161
Brain-targeted delivery shuttled by black phosphorus nanostructure to treat Parkinson's disease
Xiong, S., Li, Z., Liu, Y., Wang, Q., Luo, J., Chen, X., Xie, Z., Zhang, Y., Zhang, H., & Chen, T. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120339 · Cited by 113
Metadata
- Authors
- Raza, C., Anjum, R., & Shakeel, N. U. A.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 226
- Pages
- 77-90
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W2936059353
- Cited by
- 603
- References
- 194
- FWCI
- 32.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.